AS-OCT Guided Treatment of Diffuse CSCC

Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03515954

Enrollment

Registered

2018-05-04

Start date

2014-03-31

Completion date

2018-10-31

Last updated

2019-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conjunctival Neoplasms

Keywords

conjunctiva, squamous neoplasia, amniotic

Brief summary

A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

Detailed description

Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using ﬁbrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).

Interventions

PROCEDURETreatment of diffuse ocular surface squamous neoplasia

Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diffuse Ocular Surface Squamous Neoplasia

Exclusion criteria

* localized OSSN (less than ﬁve clock hours in limbal extent)

Design outcomes

Primary

Measure	Time frame	Description
The recurrence rate of lesion	2 years	Any recurrence which is detected clinically or/and by AS-OCT

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026